HSIC Stock Forecast 2025-2026
Distance to HSIC Price Targets
HSIC Price Momentum
🤔 Considering Henry Schein (HSIC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest HSIC Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, HSIC has a neutral consensus with a median price target of $80.00 (ranging from $55.00 to $90.00). The overall analyst rating is Buy (6.9/10). Currently trading at $70.58, the median forecast implies a 13.3% upside. This outlook is supported by 6 Buy, 8 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Michael Petusky at Barrington Research, projecting a 27.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HSIC Analyst Ratings
HSIC Price Target Range
Latest HSIC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HSIC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $80.00 |
| Feb 26, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $90.00 |
| Feb 14, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Initiates | $80.00 |
| Jan 30, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $90.00 |
| Jan 23, 2025 | Jefferies | Brandon Couillard | Hold | Maintains | $80.00 |
| Jan 6, 2025 | B of A Securities | Michael Cherny | Buy | Upgrade | $84.00 |
| Dec 4, 2024 | Mizuho | Steven Valiquette | Neutral | Initiates | $75.00 |
| Nov 6, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $82.00 |
| Oct 8, 2024 | Evercore ISI Group | Ross Muken | In-Line | Maintains | $74.00 |
| Sep 20, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $82.00 |
| Aug 12, 2024 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $80.00 |
| Aug 7, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $82.00 |
| Aug 7, 2024 | Baird | Jeff Johnson | Outperform | Maintains | $82.00 |
| Aug 7, 2024 | Evercore ISI Group | Ross Muken | In-Line | Maintains | $70.00 |
| Aug 7, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $72.00 |
| Jul 22, 2024 | Baird | Jeff Johnson | Outperform | Upgrade | $92.00 |
| Jul 9, 2024 | Evercore ISI Group | Ross Muken | In-Line | Maintains | $72.00 |
| Jul 5, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $92.00 |
| Jun 21, 2024 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $86.00 |
| May 8, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $80.00 |
Henry Schein Inc. (HSIC) Competitors
The following stocks are similar to Henry Schein based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Henry Schein Inc. (HSIC) Financial Data
Henry Schein Inc. has a market capitalization of $8.76B with a P/E ratio of 23.1x. The company generates $12.67B in trailing twelve-month revenue with a 3.1% profit margin.
Revenue growth is +5.8% quarter-over-quarter, while maintaining an operating margin of +4.9% and return on equity of +8.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Henry Schein Inc. (HSIC) Business Model
About Henry Schein Inc.
Healthcare distribution company serving dental and medical professionals.
Henry Schein operates by supplying a wide range of healthcare products and services to dental and medical practitioners. The company generates revenue through sales of dental and medical supplies, vaccines, pharmaceuticals, and healthcare equipment, alongside offering practice management solutions and technology-based services that enhance operational efficiency for healthcare practices.
Founded in 1932 and headquartered in Melville, New York, Henry Schein is a leader in healthcare distribution with a strong presence in North America and internationally. Its extensive distribution networks ensure timely delivery of essential medical products, highlighting its critical role in the global healthcare supply chain.
Company Information
Sector
Healthcare
Industry
Medical Distribution
Employees
25,000
CEO
Mr. Stanley M. Bergman CPA
Country
United States
IPO Year
1995
Website
www.henryschein.comHenry Schein Inc. (HSIC) Latest News & Analysis
HSIC exhibits strong bullish momentum, trading above its 30-week EMA with a 2.6 reward-to-risk ratio. It has institutional support and has outperformed the S&P 500 since December 2024.
HSIC's strong momentum, institutional support, and outperformance against the S&P 500 indicate potential for price appreciation, making it a compelling investment opportunity.
Henry Schein, Inc. (Nasdaq: HSIC) has been recognized as a 2025 World's Most Ethical Company by Ethisphere, marking its continued commitment to ethical practices in the healthcare sector.
Henry Schein's recognition as one of the World's Most Ethical Companies enhances its reputation, potentially attracting more customers and investors, and may lead to increased stock value.
Henry Schein, Inc. (Nasdaq: HSIC) will present at the Leerink Global Healthcare Conference on March 11, 2025, at 1:40 p.m. ET. The presentation will be accessible via live webcast.
Henry Schein's presentation at a prominent healthcare conference may influence investor sentiment and stock performance, highlighting potential growth opportunities and strategic initiatives.
Henry Schein, a leading provider of healthcare products, reported a 5.8% revenue increase in Q4 2024. Despite a 3% share dip, management's 2025 guidance suggests continued growth.
Henry Schein's consistent growth, strong Q4 revenue, and positive 2025 guidance signal resilience, making it an attractive investment despite the recent share dip.
Henry Schein projects annual profit below Wall Street estimates, citing weak demand and ongoing inflation challenges in the dental and medical products sectors.
Henry Schein's profit forecast below expectations signals weaker demand and inflationary pressures, potentially impacting stock performance and investor confidence in the company.
Henry Schein Inc. reported a Q4 adjusted EPS of $1.19, an 80.3% increase year-over-year, but fell short of the consensus estimate of $1.21.
Henry Schein's Q4 EPS growth indicates strong performance, but the miss on consensus may signal potential concerns about future earnings, impacting investor sentiment and stock valuation.
Frequently Asked Questions About HSIC Stock
What is Henry Schein Inc.'s (HSIC) stock forecast for 2025?
Based on our analysis of 22 Wall Street analysts, Henry Schein Inc. (HSIC) has a median price target of $80.00. The highest price target is $90.00 and the lowest is $55.00.
Is HSIC stock a good investment in 2025?
According to current analyst ratings, HSIC has 6 Buy ratings, 8 Hold ratings, and 1 Sell ratings. The stock is currently trading at $70.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HSIC stock?
Wall Street analysts predict HSIC stock could reach $80.00 in the next 12 months. This represents a 13.3% increase from the current price of $70.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Henry Schein Inc.'s business model?
Henry Schein operates by supplying a wide range of healthcare products and services to dental and medical practitioners. The company generates revenue through sales of dental and medical supplies, vaccines, pharmaceuticals, and healthcare equipment, alongside offering practice management solutions and technology-based services that enhance operational efficiency for healthcare practices.
What is the highest forecasted price for HSIC Henry Schein Inc.?
The highest price target for HSIC is $90.00 from Michael Petusky at Barrington Research, which represents a 27.5% increase from the current price of $70.58.
What is the lowest forecasted price for HSIC Henry Schein Inc.?
The lowest price target for HSIC is $55.00 from at , which represents a -22.1% decrease from the current price of $70.58.
What is the overall HSIC consensus from analysts for Henry Schein Inc.?
The overall analyst consensus for HSIC is neutral. Out of 22 Wall Street analysts, 6 rate it as Buy, 8 as Hold, and 1 as Sell, with a median price target of $80.00.
How accurate are HSIC stock price projections?
Stock price projections, including those for Henry Schein Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
